Buy Pfizer Stock (EXTENDED)

The market currently views Pfizer through the lens of its "COVID hangover" and an impending "patent cliff." However, for long-term investors, the current valuation may represent an attractive entry point based on three primary pillars:

For , Pfizer may remain a "dead money" asset due to the lack of immediate revenue drivers. However, for long-term value and income investors , the stock offers a rare combination of a high, sustainable yield and the potential for a significant "re-rating" once the market gains confidence in its post-2028 growth engine. buy pfizer stock

: Trading at approximately 15x to 20x estimated earnings and significantly below its pandemic-era highs, the stock is considered undervalued by several analysts. With a market cap of roughly $153.59 billion , many argue the downside risk is cushioned by the existing pessimistic sentiment. The market currently views Pfizer through the lens